Inventor
LESCOP CYRILLE
CH15 patents
⚠️ This page may combine multiple inventors who share the name “LESCOP CYRILLE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BOLLI MARTIN
7 patentsUS8299086B2Oct 30, 2012
Pyrimidine derivatives
BOLLI MARTIN14 citations84
US8148410B2Apr 3, 2012
Thiophene derivatives as agonists of S1P1/EDG1
BOLLI MARTIN11 citations84
US8658675B2Feb 25, 2014
Pyridin-4-yl derivatives
BOLLI MARTIN7 citations83
US8575200B2Nov 5, 2013
Pyridin-2-yl derivatives as immunomodulating agents
BOLLI MARTIN6 citations73
US8410151B2Apr 2, 2013
Aminomethyl benzene derivatives
BOLLI MARTIN6 citations73
US9133179B2Sep 15, 2015
2-methoxy-pyridin-4-yl-derivatives
BOLLI MARTIN5 citations72
US8598208B2Dec 3, 2013
Pyridine derivatives as S1P1/EDG1 receptor modulators
BOLLI MARTIN6 citations72
IDORSIA PHARMACEUTICALS LTD
7 patentsUS10385043B2Aug 20, 2019
Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
IDORSIA PHARMACEUTICALS LTD4 citations83
US12344597B2Jul 1, 2025
Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis
IDORSIA PHARMACEUTICALS LTD2 citations74
US11390615B2Jul 19, 2022
Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
IDORSIA PHARMACEUTICALS LTD1 citations72
US10836754B2Nov 17, 2020
Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
IDORSIA PHARMACEUTICALS LTD1 citations72
US11834443B2Dec 5, 2023
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
IDORSIA PHARMACEUTICALS LTD0 citations61
US12479820B2Nov 25, 2025
Pyridin-3-yl derivatives
IDORSIA PHARMACEUTICALS LTD0 citations51
US12539294B2Feb 3, 2026
Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
IDORSIA PHARMACEUTICALS LTD0 citations41